Company profile: ReadyCell
1.1 - Company Overview
Company description
- Provider of cell-based in vitro tools and drug discovery services, including: CacoReady, a ready-to-use Caco-2 kit for assessing intestinal permeability in preclinical studies; CacoGoblet, a Caco-2/HT-29 co-culture to evaluate intestinal absorption and anti-inflammatory drug efficacy; PreadyPort, MDCKII-based kits to study permeability and MDR1/BCRP efflux; PreadyTake, HEK293 transporter-overexpressing kits (MATE1, OCT2, OATP1B3).
Products and services
- CacoGoblet: Cell-based co-culture model of Caco-2 and HT-29 cells to evaluate intestinal absorption and assess anti-inflammatory drug efficacy in assays
- CacoReady: In vitro ready-to-use kit containing Caco-2 cells to assess intestinal permeability of oral drugs in preclinical studies
- PreadyPort: MDCKII-based kits that evaluate drug permeability and characterize efflux transporter interactions, including MDR1 and BCRP, in cell culture experiments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ReadyCell
GlycoFi
HQ: United States
Website
- Description: Provider of biotherapeutic development based on glycan optimization technology and a yeast-based glycosylation protein manufacturing process, aiming to build its own pipeline of therapeutic proteins and partner with other drug-makers to develop products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoFi company profile →
Immunophotonics
HQ: United States
Website
- Description: Provider of immunotherapy-based cancer treatments, including IP-001, a proprietary glycan polymer that stimulates immune responses against cancer and infectious diseases by acting as an antigen depot and immune activator; and an Abscopalizing Technique involving IP-001 injection with tumor ablation or radiation to induce a systemic immune response against cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunophotonics company profile →
MILabs
HQ: The Netherlands
Website
- Description: Provider of high-end molecular imaging solutions for biomedical research, including systems for quantitative 3D functional imaging of SPECT (U-SPECT) and PET (U-PET) tracers, an integrated PET/SPECT platform for simultaneous high-resolution imaging (VECTor), and automated quantitative 3D autoradiography of tissue samples with multiple isotopes (EXIRAD-3D).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MILabs company profile →
B-MoGen
HQ: United States
Website
- Description: Provider of genome engineering solutions, including the TcBuster Transposon System, a non-viral genetic modification method for delivering therapeutic payloads to diverse cell types, enabling rapid transgenic mammalian cell generation, multigene transfer, and CRISPR-mediated knockouts; and ScaleReady, a partnership that reduces complexity and cost in immune cell therapy and supports scalable immune cell expansion with platform, process, and product continuity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full B-MoGen company profile →
Breath Therapeutics
HQ: Germany
Website
- Description: Provider of inhaled investigational therapies for rare respiratory diseases, combining novel formulations of existing drugs with cutting-edge inhalation technology. Pipeline includes Liposomal Cyclosporine A for Inhalation for bronchiolitis obliterans syndrome to deliver drug to lungs while minimizing systemic exposure, and inhaled colistimethate sodium for non-cystic fibrosis bronchiectasis targeting Pseudomonas aeruginosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Breath Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ReadyCell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ReadyCell
2.2 - Growth funds investing in similar companies to ReadyCell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ReadyCell
4.2 - Public trading comparable groups for ReadyCell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →